At Silence, we aim to transform peoples’ lives around the world by silencing diseases through our precision-engineered medicines and driving positive change for the communities around us.
We are currently enrolling participants into a phase 2 study (SANRECO) for divesiran to treat polycythema vera (PV). Divesiran works by targeting genes to increase your natural hepcidin levels, a hormone that is the “Gate-Keeper” of iron in the body.
Increased hepcidin means:
-
Less available iron reducing PV symptoms such as fatigue, brain fog, and itchy skin.
-
Reducing phlebotomies.
-
Lowering the risk of blood clots and strokes.
If you meet these following abbreviated lists of the eligibility requirements, you may be able to participate in the study:
-
≥ 18 years old.
-
Confirmed Polycythemia Vera diagnosis (2016 WHO criteria).
-
Had 3 or more phlebotomies in the last 7 months, or 5 or more in the last 12 months.
-
Treated with cytoreductives if being treated with a stable dose.
Study centres are now being open in the following countries: USA, Canada, UK, Poland, Bulgaria, Spain, Germany, Italy, Australia and Malaysia. For more information about divesiran, the SANRECO study, and study centre locations, please visit Study Details | Study to Assess SLN124 in Patients With Polycythemia Vera | ClinicalTrials.gov, www.sanrecopvstudy.com and www.silence-therapeutics.com.